Mavezelimab/Pembrolizumab

玛维泽利单抗/帕博利珠单抗

Report date: 2025/10/20 15:48:33

Base Information

Drug NameMavezelimab/Pembrolizumab
Drug Alias NameCoformulation favezelimab/pembrolizumabPembrolizumab/favezelimabfavezelimab/pembrolizumabMK-4280AMK-4820A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitorsProgrammed cell death protein 1 blockers
TargetsLymphocyte activation gene 3 proteinProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisEndometrial Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsYes MavezelimabPembrolizumab
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMsd Ireland (Carlow)Merck Sharp & Dohme CorpMerck Sharp & Dohme LLC +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsSmall Cell Lung Carcinoma +[8] 
Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksN/A